Promising findings towards targeted breast cancer therapy

November 14, 2016

New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple negative breast cancer.

This research has identified a potential new for a form of known as triple negative breast cancer and which is currently difficult to treat. This new drug treatment known as APR-246 acts by blocking a mutant gene responsible for the driving the growth of triple-negative breast cancers.

Major progress has been made in the treatment of most forms of breast cancer in recent years. However, the triple negative form still remains difficult to treat. Approximately, 250 women are diagnosed with this form of breast cancer each year in Ireland.

Currently, the only form of drug-related therapy available for these is chemotherapy. The aim of this work was to identify a therapy specifically inhibiting genes involved in the growth of these cancers.

PhD student, Naoise Synnott tested the effects of APR-246 on cancer cells grown in the laboratory. Building on the findings of this study, the team hope that this drug can be tested as part of a clinical trial in patients with triple-negative breast cancer.

"I decided to focus my BREAST-PREDICT research on triple-negative breast cancer because it was clear that work needed to be done to provide better and more targeted treatment for these patients. I hope that (our) work will be a big step in providing better treatment and hope to future triple-negative ."

Commenting on the findings, Professor Duffy, UCD Clinical Research Centre and St Vincent's University Hospital said, "If the laboratory data can be confirmed in a clinical trial, APR-246 could be the first non-chemotherapy drug used in the treatment of patients with this form of breast cancer",

Professor William Gallagher, Director of BREAST-PREDICT and UCD Conway Institute, added: "Over the last two decades, drugs such as Herceptin have been discovered to target or block proteins that are responsible for the growth of some breast cancers. However, finding a similar drug therapy for triple-negative breast cancer has so far alluded scientists, making these findings all the more important. If successful in clinical trials, APR-246 will be shown to have been effective in targeting a gene known as p53, a gene that is altered in almost all cases of triple-negative breast cancer."

A mutation of the p53 gene occurs in around 80% of these triple-negative breast cancers. Naoise and her colleagues have now shown that APR-246 can act by correcting or neutralising the mutant form of p53, which in turn stops the growth of cells grown in the laboratory.

Explore further: Discovery of potential treatment for aggressive form of breast cancer

More information: N.C. Synnott et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?, International Journal of Cancer (2017). DOI: 10.1002/ijc.30425

Related Stories

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.